AcquisitionsApr 29, 2026, 06:32 AM
TEVA Acquires Emalex for $700M Upfront; Adds Tourette Syndrome Drug
AI Summary
Teva Pharmaceuticals announced a definitive agreement to acquire Emalex Biosciences, including its lead asset ecopipam, an investigational drug for pediatric Tourette syndrome. Teva will pay $700 million in cash upfront, with Emalex shareholders eligible for up to an additional $200 million in commercial milestone payments and royalties on global net sales. Ecopipam has shown positive Phase 3 data, received FDA Orphan Drug and Fast Track designations, and its NDA submission is expected in the second half of 2026. This acquisition aligns with Teva's "Pivot to Growth" strategy, expanding its innovative medicines pipeline in neuroscience, and is expected to close by Q3 2026.
Key Highlights
- Teva to acquire Emalex Biosciences for its lead asset, ecopipam, for pediatric Tourette syndrome.
- Upfront payment of $700 million in cash to Emalex shareholders.
- Emalex shareholders eligible for up to an additional $200 million in commercial milestone payments.
- Emalex shareholders will also receive royalties on global net sales of ecopipam.
- Ecopipam has positive Phase 3 data and NDA submission is anticipated in 2H 2026.
- Ecopipam holds FDA Orphan Drug and Fast Track designations.
- Transaction is expected to close by Q3 2026, funded by cash on hand.